Regeneron in $1bn RNAi pact with Alnylam
Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.
Archives for April 9, 2019
EU approval for Teva’s quarterly dosed migraine drug
Teva’s anti-CGRP migraine drug lines up next to its competitors as the European Commission grants it marketing authorization.
Transgene and BioInvent extend OV development for solid tumor collaboration
Transgene and BioInvent will extend their collaboration to co-develop multi-functional oncolytic viruses for the treatment of solid tumors.